The Third Xiangya Hospital Of Central South University
Clinical trials sponsored by The Third Xiangya Hospital Of Central South University, explained in plain language.
-
Can a new pain drug safely team up with an opioid?
Disease control Not yet recruitingThis trial is testing an investigational drug called KL0011034, given by infusion, alongside the opioid alfentanil in people with moderate-to-severe chronic pain that is not caused by cancer. The study aims to see how the two drugs interact in the body, and whether the combinatio…
Phase: PHASE1 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug make anesthesia safer and more effective?
Disease control Not yet recruitingThis trial tests an experimental drug called HRS-9190 to see if it can relax muscles enough for placing a breathing tube and keep them relaxed during surgery. It compares HRS-9190 to a standard muscle relaxant, rocuronium, in adults having planned surgery under general anesthesia…
Phase: PHASE3 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Nurse coaching may help heart failure patients avoid hospital visits by mastering fluid control
Disease control Not yet recruitingThis trial tests a nurse-led program designed to help people with chronic heart failure better manage fluid buildup—a common cause of hospital readmission. The program includes education, emotional support, and practical skills like daily weighing and salt restriction. Researcher…
Phase: NA • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug cocktail aims to boost lung cancer treatment before radiation
Disease control Not yet recruitingThis Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction…
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Smart sensors vs. finger pricks: which works better for diabetes?
Disease control Not yet recruitingThis study compares two glucose monitoring methods—continuous glucose monitors (CGM) and traditional finger-prick tests—in adults with type 2 diabetes who are taking the drug dapagliflozin. The 120 participants will be split into two groups and followed for 12 weeks to see which …
Phase: NA • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a fungus slow ALS? new trial targets high sphingolipids
Disease control Not yet recruitingThis study tests an oral traditional Chinese medicine made from the fungus C. cicadae in people with ALS who have high levels of certain fats (sphingolipids) in their blood. About 84 participants will receive either the medicine or a placebo for 6 months, with follow-up for 9 mon…
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Smart drug choice: matching pills to your heart type may beat standard BP care
Disease control Not yet recruitingThis study tests whether choosing blood pressure medication based on a person's specific heart and blood vessel measurements (hemodynamic phenotyping) works better than the usual guideline-based approach. About 240 adults with mild-to-moderate hypertension who have never taken bl…
Phase: PHASE4 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental vaccine takes on tough pancreatic cancer
Disease control Not yet recruitingThis early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goal is to check safety, b…
Phase: EARLY_PHASE1 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a Partner's support lower diabetes risk after gestational diabetes?
Prevention Not yet recruitingThis trial tests whether a lifestyle program that includes the partner can help women who had gestational diabetes improve their weight and blood sugar control. Participants receive three months of health education on diet, physical activity, and stress management, with one group…
Phase: NA • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Could a new drug alter the fate of common medications?
Knowledge-focused Not yet recruitingThis Phase 1 trial in about 18 healthy adults tests whether taking NTQ5082 capsules changes how the body processes midazolam, a short-acting sedative used as a probe to measure liver enzyme activity. Participants receive midazolam alone and then alongside single and repeated dose…
Phase: PHASE1 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC